Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy Volunteers

Healthy Volunteers Clinical Trial

Official title:

A Randomized, Double-blinded, Controlled, Single Dosing Phase I Study to Investigate The Pharmacokinetic, Safety and Immunogenicity Characteristics of CMAB809 and Herceptin in Healthy Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04049409
• Other study ID #: CMAB809HV-I
• Status: Completed
• Phase: Phase 1
• Start date: June 17, 2019
• Est. completion date: November 20, 2019

Study information

• Verified date: October 2020
• Source: Taizhou Mabtech Pharmaceutical Co.,Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blinded, controlled Phase I study of CMAB809 administered by intravenous infusion. This study will characterize the pharmacokinetic, safety and immunogenicity of CMAB809 versus Trastuzumab(Herceptin) in healthy male subjects after a single dose.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 72
• Est. completion date: November 20, 2019
• Est. primary completion date: November 20, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy male volunteers, age ranged 18 to 45 years (both inclusive)

• A subject with body weight be equal or greater than 50 kg (inclusive) and body mass index (BMI) between 19 and 26 kg/m2 (both inclusive)

• Findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the laboratory reference ranges for the relevant laboratory tests (unless the investigator considers the deviation to be irrelevant for the purpose of the study)

• Left ventricular ejection fraction (LVEF) within the normal range by echocardiogram (ECHO) at 2 weeks prior to randomization

• The subjects have the ability to understand the full characteristics and objectives of the study, including the possible risks and side effects of the study; Moreover, the subjects can communicate well with researchers and complete the research according to the regulations

• Subjects must voluntarily sign ICF prior to the study

Exclusion Criteria:

• Any clinical signs and symptoms (including blood pressure, pulse, and electrocardiogram) found during medical examination; And those who underwent surgery within 4 weeks before screening; Or plans to operate during the trial period

• Diagnosed with any clinical history of serious illness or any other disease or physiological conditions which can interfere with the test results

• Prescription or over-the-counter drugs with a long half-life (greater than 24h) within 1 month prior to administration. Take any other medication that the investigator considers may affect the subject's enrollment within 2 weeks prior to administration. A subject who has participated in any other clinical trial within 3 months before the study drug administration

• Have used or are using biological products such as monoclonal antibodies or fusion proteins

• Patients who have or have had chronic hepatitis b, c, syphilis or HIV infection, or who have tested positive for the above infection were deemed unsuitable to participate in this study

• Those who had been vaccinated within 30 days prior to screening or who needed to be vaccinated between screening and the end of the trial

• Drug abusers, or those who used soft drugs (e.g., marijuana) 3 months before screening, or took hard drugs (e.g., cocaine, phenyclohexidine, etc.) 1 year before the test, or drank excessive amounts of tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup =250ml) every day, or those who showed positive urine drug screening

• Blood donation (containing component blood) or lost more than 400 mL of blood within 3 months before screening, or blood transfusion; Blood donation (containing component blood) or blood loss of more than 200 mL within 1 month before screening

• Related allergies (including allergy to any mouse\human protein or immunoglobulin products, rubber or latex)

• Those who smoked more than 10 cigarettes per day within 6 months before screening; And those who could not quit during the study period

• Alcoholics (who drink more than 14 standard units per week), or who have positive result in breath-test of alcohol

• Vigorous activity for 72h before drug administration; and cannot be avoided within 7 days after drug administration

• Unable to accept clinical trial center diet

• Fertile men who were unwilling to use highly effective contraceptives during the trial and for five months after administration

• The investigator judges the subject not eligible for the study after reviewing clinical laboratory results or other reasons

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• CMAB809
CMAB809 will be administered by IV infusion at a single dose of 6mg/kg.
• Trastuzumab
Trastuzumab will be administered by IV infusion at a single dose of 6mg/kg.

Locations

Country	Name	City	State
China	Shanghai Xuhui Central Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Taizhou Mabtech Pharmaceutical Co.,Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Percentage of participants with Adverse Events	Percentage of participants with Adverse Events (AEs) according to National Cancer Institute Common Terminology Criteria for AEs, Version 5.0(NCI CTCAE V5.0) Common Terminology Criteria for AEs, Version 5.0 (NCI CTCAE V5.0)	Up to 71 days after administration
Other	anti-drug antibodies(ADA)	The number of subjects will be summarized	pre-dose, week3, week5 and week11 post-dose
Other	anti-drug antibodies(ADA)	The percentage of subjects will be summarized	pre-dose, week3, week5 and week11 post-dose
Other	Neutralization antibodies(Nab)	The number of subjects will be summarized	pre-dose, week3, week5 and week11 post-dose
Other	Neutralization antibodies(Nab)	The percentage of subjects will be summarized	pre-dose, week3, week5 and week11 post-dose
Primary	Area under the concentration-time curve [AUC]	Area under the concentration-time curve [AUC] from 0 to the last time point selected of CMAB809	pre-dose, hour1.5, hour3, hour8, hour24, hour48, hour96, hour168, hour336, hour504, hour672, hour1008, hour1344, hour1680 post-dose
Secondary	Cmax	Maximum Serum Concentration(Cmax) of CMAB809	pre-dose, hour1.5, hour3, hour8, hour24, hour48, hour96, hour168, hour336, hour504, hour672, hour1008, hour1344, hour1680 post-dose
Secondary	AUC0-8	Area under the concentration-time curve from 0 to inf(AUC0-8) of CMAB809	pre-dose, hour1.5, hour3, hour8, hour24, hour48, hour96, hour168, hour336, hour504, hour672, hour1008, hour1344, hour1680 post-dose
Secondary	Tmax	The time of maximum blood concentration after administration(Tmax) of CMAB809	pre-dose, hour1.5, hour3, hour8, hour24, hour48, hour96, hour168, hour336, hour504, hour672, hour1008, hour1344, hour1680 post-dose
Secondary	CL	Total clearance after bioavailability correction(CL) of CMAB809	pre-dose, hour1.5, hour3, hour8, hour24, hour48, hour96, hour168, hour336, hour504, hour672, hour1008, hour1344, hour1680 post-dose
Secondary	T1/2	Half-life(T1/2) of CMAB809	pre-dose, hour1.5, hour3, hour8, hour24, hour48, hour96, hour168, hour336, hour504, hour672, hour1008, hour1344, hour1680 post-dose
Secondary	Vd	Apparent volume of distribution corrected for bioavailability(Vd) of CMAB809	pre-dose, hour1.5, hour3, hour8, hour24, hour48, hour96, hour168, hour336, hour504, hour672, hour1008, hour1344, hour1680 post-dose